Details of the Drug

General Information of Drug (ID: DMI4EL5)

Drug Name
Ketorolac
Synonyms
Ketoralac; Ketorolaco; Ketorolacum; Macril; Ketorolaco [Spanish]; Ketorolacum [Latin]; RS 37619; Acular (TN); Ketorolac (INN); Ketorolac [INN:BAN]; RS-37619; Toradol (TN); (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; (+-)-Ketorolac; (+-)-isomer; (+/-)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro; 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Postoperative inflammation 1A00-CA43.1 Approved [1]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 255.27
Topological Polar Surface Area (xlogp) 1.9
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 20-60 min [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability
The bioavailability of drug is 80% [2]
Clearance
The clearance of drug is 0.021-0.037 L/h/kg [2]
Elimination
Ketorolac is primarily renally eliminated and approximately 92% of the dose can be recovered in the urine with 60% of this proportion recovered unchanged, and 40% recovered as metabolites [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.5 hours [4]
Metabolism
The drug is metabolized via the hydroxylation or conjugation in the liver [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 9.79333 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.0068% [7]
Vd
The volume of distribution (Vd) of drug is 0.25 L/kg [2]
Water Solubility
The ability of drug to dissolve in water is measured as 200 mg/mL [3]
Chemical Identifiers
Formula
C15H13NO3
IUPAC Name
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
Canonical SMILES
C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O
InChI
InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)
InChIKey
OZWKMVRBQXNZKK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3826
ChEBI ID
CHEBI:76223
CAS Number
74103-06-3
DrugBank ID
DB00465
TTD ID
D0D9JW
INTEDE ID
DR0908
ACDINA ID
D00344

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase (COX) TTK0943 PGH1_HUMAN; PGH2_HUMAN Inhibitor [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C8 (CYP2C8)
Main DME 		DES5XRU CP2C8_HUMAN Substrate [9]
UDP-glucuronosyltransferase 2B7 (UGT2B7)
Main DME 		DEB3CV1 UD2B7_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ketorolac
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Prednisone DM2HG4X Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ketorolac and Prednisone. Postoperative inflammation [1A00-CA43] [36]
Hydrocortisone DMGEMB7 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ketorolac and Hydrocortisone. Postoperative inflammation [1A00-CA43] [36]
Coadministration of a Drug Treating the Disease Different from Ketorolac (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Ketorolac and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [37]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Ketorolac and Repaglinide. Acute diabete complication [5A2Y] [38]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Ketorolac and Glibenclamide. Acute diabete complication [5A2Y] [38]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Ketorolac and Tolazamide. Acute diabete complication [5A2Y] [38]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Ketorolac and Nateglinide. Acute diabete complication [5A2Y] [38]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Ketorolac and Glipizide. Acute diabete complication [5A2Y] [38]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Ketorolac and Inotersen. Amyloidosis [5D00] [39]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Ketorolac and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [40]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Ketorolac and Cilostazol. Arterial occlusive disease [BD40] [41]
Ofloxacin DM0VQN3 Moderate Additive CNS depression effects by the combination of Ketorolac and Ofloxacin. Bacterial infection [1A00-1C4Z] [42]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Kanamycin. Bacterial infection [1A00-1C4Z] [43]
Ciprofloxacin XR DM2NLS9 Moderate Additive CNS depression effects by the combination of Ketorolac and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [42]
Amikacin DM5PDRB Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Amikacin. Bacterial infection [1A00-1C4Z] [43]
Trovafloxacin DM6AN32 Moderate Additive CNS depression effects by the combination of Ketorolac and Trovafloxacin. Bacterial infection [1A00-1C4Z] [42]
Sparfloxacin DMB4HCT Moderate Additive CNS depression effects by the combination of Ketorolac and Sparfloxacin. Bacterial infection [1A00-1C4Z] [42]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Streptomycin. Bacterial infection [1A00-1C4Z] [43]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Ketorolac and Gemifloxacin. Bacterial infection [1A00-1C4Z] [42]
Norfloxacin DMIZ6W2 Moderate Additive CNS depression effects by the combination of Ketorolac and Norfloxacin. Bacterial infection [1A00-1C4Z] [42]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Ketorolac and ABT-492. Bacterial infection [1A00-1C4Z] [42]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Gentamicin. Bacterial infection [1A00-1C4Z] [43]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Netilmicin. Bacterial infection [1A00-1C4Z] [43]
Levofloxacin DMS60RB Moderate Additive CNS depression effects by the combination of Ketorolac and Levofloxacin. Bacterial infection [1A00-1C4Z] [42]
Tobramycin DMUI0CH Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Tobramycin. Bacterial infection [1A00-1C4Z] [43]
Lomefloxacin DMVRH9C Moderate Additive CNS depression effects by the combination of Ketorolac and Lomefloxacin. Bacterial infection [1A00-1C4Z] [42]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Etidronic acid. Bone paget disease [FB85] [44]
Risedronate DM5FLTY Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Risedronate. Bone paget disease [FB85] [44]
Alendronate DMY2KX9 Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Alendronate. Bone paget disease [FB85] [44]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Ketorolac and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [45]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Ketorolac and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [41]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Ketorolac and Iodipamide. Cholelithiasis [DC11] [46]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Ketorolac and Levomilnacipran. Chronic pain [MG30] [47]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Ketorolac and Anisindione. Coagulation defect [3B10] [41]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Ketorolac and Regorafenib. Colorectal cancer [2B91] [39]
Oxaliplatin DMQNWRD Moderate Decreased renal excretion of Ketorolac caused by Oxaliplatin mediated nephrotoxicity. Colorectal cancer [2B91] [48]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Ketorolac and Drospirenone. Contraceptive management [QA21] [49]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Methoxyflurane. Corneal disease [9A76-9A78] [39]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Ketorolac and Ardeparin. Coronary thrombosis [BA43] [50]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Ketorolac and Danaparoid. Deep vein thrombosis [BD71] [50]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Ketorolac and Rivaroxaban. Deep vein thrombosis [BD71] [51]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Ketorolac and Sertraline. Depression [6A70-6A7Z] [47]
Fluoxetine DM3PD2C Moderate Increased risk of bleeding by the combination of Ketorolac and Fluoxetine. Depression [6A70-6A7Z] [47]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Ketorolac and Vilazodone. Depression [6A70-6A7Z] [47]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Ketorolac and Paroxetine. Depression [6A70-6A7Z] [47]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Ketorolac and Vortioxetine. Depression [6A70-6A7Z] [47]
Duloxetine DM9BI7M Moderate Increased risk of bleeding by the combination of Ketorolac and Duloxetine. Depression [6A70-6A7Z] [47]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Ketorolac and Milnacipran. Depression [6A70-6A7Z] [47]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Ketorolac and Escitalopram. Depression [6A70-6A7Z] [47]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Ketorolac and Desvenlafaxine. Depression [6A70-6A7Z] [47]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Ketorolac and Clomipramine. Depression [6A70-6A7Z] [47]
PMID28870136-Compound-49 DMTUC9E Major Increased risk of bleeding by the combination of Ketorolac and PMID28870136-Compound-49. Discovery agent [N.A.] [52]
Fenfluramine DM0762O Moderate Increased risk of bleeding by the combination of Ketorolac and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [47]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Ketorolac and Cannabidiol. Epileptic encephalopathy [8A62] [39]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Ketorolac when combined with Ethacrynic acid. Essential hypertension [BA00] [53]
Benzthiazide DMQWZ0H Moderate Antagonize the effect of Ketorolac when combined with Benzthiazide. Essential hypertension [BA00] [53]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Ketorolac and Tazemetostat. Follicular lymphoma [2A80] [41]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Ketorolac and Avapritinib. Gastrointestinal stromal tumour [2B5B] [39]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Ketorolac and Sulfinpyrazone. Gout [FA25] [41]
Eplerenone DMF0NQR Moderate Antagonize the effect of Ketorolac when combined with Eplerenone. Heart failure [BD10-BD1Z] [54]
Chlorothiazide DMLHESP Moderate Antagonize the effect of Ketorolac when combined with Chlorothiazide. Heart failure [BD10-BD1Z] [53]
Furosemide DMMQ8ZG Moderate Antagonize the effect of Ketorolac when combined with Furosemide. Heart failure [BD10-BD1Z] [53]
Amiloride DMRTSGP Moderate Antagonize the effect of Ketorolac when combined with Amiloride. Heart failure [BD10-BD1Z] [53]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Ketorolac when combined with Bumetanide. Heart failure [BD10-BD1Z] [53]
Hydroflumethiazide DMVPUQI Moderate Antagonize the effect of Ketorolac when combined with Hydroflumethiazide. Heart failure [BD10-BD1Z] [53]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Ketorolac and Brentuximab vedotin. Hodgkin lymphoma [2B30] [55]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Ketorolac and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [56]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Ketorolac and Mipomersen. Hyper-lipoproteinaemia [5C80] [57]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Ketorolac and Teriflunomide. Hyper-lipoproteinaemia [5C80] [58]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Ketorolac and BMS-201038. Hyper-lipoproteinaemia [5C80] [59]
Indapamide DMGN1PW Moderate Antagonize the effect of Ketorolac when combined with Indapamide. Hypertension [BA00-BA04] [53]
Trichlormethiazide DMHAQCO Moderate Antagonize the effect of Ketorolac when combined with Trichlormethiazide. Hypertension [BA00-BA04] [53]
Hydrochlorothiazide DMUSZHD Moderate Antagonize the effect of Ketorolac when combined with Hydrochlorothiazide. Hypertension [BA00-BA04] [53]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Ketorolac and Dipyridamole. Hypertension [BA00-BA04] [41]
Potassium chloride DMMTAJC Moderate Increased risk of hyperkalemia by the combination of Ketorolac and Potassium chloride. Hypo-kalaemia [5C77] [60]
Fludrocortisone DMUDIR8 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ketorolac and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [36]
Balsalazide DMO091F Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Balsalazide. Indeterminate colitis [DD72] [61]
Methotrexate DM2TEOL Major Increased risk of nephrotoxicity by the combination of Ketorolac and Methotrexate. Leukaemia [2A60-2B33] [62]
Ibandronate DM0QZBN Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Ibandronate. Low bone mass disorder [FB83] [39]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Ketorolac and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [63]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Ketorolac and Idelalisib. Mature B-cell leukaemia [2A82] [64]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Ketorolac and Acalabrutinib. Mature B-cell lymphoma [2A85] [65]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Ketorolac and Clofarabine. Mature B-cell lymphoma [2A85] [39]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Ketorolac and Ibrutinib. Mature B-cell lymphoma [2A85] [66]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Ketorolac and Ponatinib. Mature B-cell lymphoma [2A85] [67]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Ketorolac and Exjade. Mineral absorption/transport disorder [5C64] [68]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Ketorolac and Panobinostat. Multiple myeloma [2A83] [37]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ketorolac and Deflazacort. Muscular dystrophy [8C70] [36]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Ketorolac and Ruxolitinib. Myeloproliferative neoplasm [2A20] [41]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Ketorolac and Dasatinib. Myeloproliferative neoplasm [2A20] [69]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Ketorolac and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [70]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Ketorolac and Prasugrel. Myocardial infarction [BA41-BA43] [39]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Ketorolac and Vorapaxar. Myocardial infarction [BA41-BA43] [71]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Ketorolac and Tirofiban. Myocardial infarction [BA41-BA43] [72]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Ketorolac and Sibutramine. Obesity [5B80-5B81] [47]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Ketorolac and Dexfenfluramine. Obesity [5B80-5B81] [47]
Metolazone DMB39LO Moderate Antagonize the effect of Ketorolac when combined with Metolazone. Oedema [MG29] [53]
Polythiazide DMCH80F Moderate Antagonize the effect of Ketorolac when combined with Polythiazide. Oedema [MG29] [53]
Diclofenac DMPIHLS Moderate Increased risk of hepatotoxicity by the combination of Ketorolac and Diclofenac. Osteoarthritis [FA00-FA05] [73]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Ketorolac and MK-4827. Ovarian cancer [2C73] [39]
Aspirin DM672AH Moderate Increased risk of bleeding by the combination of Ketorolac and Aspirin. Pain [MG30-MG3Z] [41]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Ketorolac and Epoprostenol. Pulmonary hypertension [BB01] [74]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Ketorolac and Iloprost. Pulmonary hypertension [BB01] [74]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Ketorolac and Everolimus. Renal cell carcinoma [2C90] [75]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Ketorolac and Temsirolimus. Renal cell carcinoma [2C90] [75]
Gatifloxacin DMSL679 Moderate Additive CNS depression effects by the combination of Ketorolac and Gatifloxacin. Respiratory infection [CA07-CA4Z] [42]
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Sulfasalazine. Rheumatoid arthritis [FA20] [61]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ketorolac and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [36]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ketorolac and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [36]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ketorolac and Pitolisant. Somnolence [MG42] [39]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Ketorolac and Naltrexone. Substance abuse [6C40] [76]
Warfarin DMJYCVW Moderate Increased risk of bleeding by the combination of Ketorolac and Warfarin. Supraventricular tachyarrhythmia [BC81] [41]
Plicamycin DM7C8YV Moderate Increased risk of bleeding by the combination of Ketorolac and Plicamycin. Testicular cancer [2C80] [41]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Ketorolac and Caplacizumab. Thrombocytopenia [3B64] [41]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Ketorolac and Apixaban. Thrombosis [DB61-GB90] [39]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Ketorolac and Cangrelor. Thrombosis [DB61-GB90] [41]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Ketorolac and Brilinta. Thrombosis [DB61-GB90] [39]
Clopidogrel DMOL54H Moderate Increased risk of bleeding by the combination of Ketorolac and Clopidogrel. Thrombosis [DB61-GB90] [41]
Cabozantinib DMIYDT4 Moderate Increased risk of bleeding by the combination of Ketorolac and Cabozantinib. Thyroid cancer [2D10] [41]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Ketorolac and Sirolimus. Transplant rejection [NE84] [75]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Ketorolac and Tacrolimus. Transplant rejection [NE84] [75]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Ketorolac and Tolbutamide. Type 2 diabetes mellitus [5A11] [38]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Ketorolac and Chlorpropamide. Type 2 diabetes mellitus [5A11] [38]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Olsalazine. Ulcerative colitis [DD71] [61]
Cinoxacin DM4EWNS Moderate Additive CNS depression effects by the combination of Ketorolac and Cinoxacin. Urinary tract infection [GC08] [42]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Ketorolac and Plazomicin. Urinary tract infection [GC08] [43]
Nalidixic acid DMRM0JV Moderate Additive CNS depression effects by the combination of Ketorolac and Nalidixic acid. Urinary tract infection [GC08] [42]
Enoxacin DMYTE6L Moderate Additive CNS depression effects by the combination of Ketorolac and Enoxacin. Urinary tract infection [GC08] [42]
Triamcinolone DM98IXF Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ketorolac and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [36]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Ketorolac and Betrixaban. Venous thromboembolism [BD72] [77]
⏷ Show the Full List of 128 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ketorolac 10 mg tablet 10 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Buckley MM, Brogden RN: Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1990 Jan;39(1):86-109. doi: 10.2165/00003495-199039010-00008.
3 BDDCS applied to over 900 drugs
4 FDA Approved Drug Products: Toradol (ketorolac tromethamine) oral tablets
5 Au WY, Dring LG, Grahame-Smith DG, Isaac P, Williams RT: The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects. Biochem J. 1972 Aug;129(1):1-10. doi: 10.1042/bj1290001.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32.
9 Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. Br J Clin Pharmacol. 2017 Sep;83(9):1966-1975.
10 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
11 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
12 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
14 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
15 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
16 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
17 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
18 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
19 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
22 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
23 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
24 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
25 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
26 Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55.
27 Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82.
28 Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77.
29 Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64.
30 Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7.
31 The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
32 Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.
33 The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.
34 Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9.
35 Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):409-15.
36 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
37 Cerner Multum, Inc. "Australian Product Information.".
38 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
39 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
40 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
41 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
42 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
43 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
44 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
45 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
46 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
47 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
48 Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
49 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
50 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
51 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
52 Product Information. Toradol (ketorolac). Roche Laboratories, Nutley, NJ.
53 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
54 Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
55 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
56 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
57 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
58 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
59 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
60 Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
61 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
62 Adams JD, Hunter GA "Drug interaction in psoriasis." Australas J Dermatol 17 (1976): 39-40. [PMID: 1022213]
63 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
64 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
65 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
66 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
67 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
68 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
69 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
70 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
71 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
72 Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
73 Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
74 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
75 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
76 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
77 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.